Pilot study of markers for high-grade anal dysplasia in a southern cohort from the Women's Interagency HIV Study (WIHS).
Anal cancer rates have increased, particularly in HIV-positive (HIV+) women. We assessed factors associated with anal precancer in HIV+ and at-risk HIV-negative (ARHIVN) women from the Atlanta Women's Interagency HIV Study Cohort. All participants underwent high resolution anoscopy, anal cytology (AC) and had anal (AS) and cervical (CS) samples collected. Specimens were tested for 37 HPV types and for FAM19A4 and microRNA124-2 promoter methylation. Binary logistic regression and multivariate analysis were conducted with histologic anal high grade squamous intraepithelial lesion (A-HSIL) as the dependent variable. Seventy-five women enrolled: 52(69%) were HIV+ with three-fourths having undetectable viral load, 64(86%) were black, with mean age 49±8 years. Forty-nine (65%) AC samples were abnormal, and 38(51%) of AS were positive for at least one of 13 high-risk HPV (hrHPV) types. Thirteen (18%) anal biopsies identified A-HSIL. Hypermethylation of FAM19A4 and/or microRNA124-2 was found in 69 (95%) AS and 19(26%) CS. In multivariate analyses, the odds of having A-HSIL were over 6 times higher in women with anal hrHPV (aOR 6.08, 95% CI 1.27-29.18, p=0.02) and with positive cervical methylation (aOR 6.49, 95% CI 1.66-25.35, p=0.007), but not significantly higher in women with positive anal methylation. Anal hrHPV and promoter hypermethylation in the cervix show promise as biomarkers for anal cancer screening in HIV+ and ARHIVN women. Greater understanding of gene silencing by promoter hypermethylation in anal carcinogenesis is needed.